ImmunityBio stock jumps before the open after FDA outlines next step for ANKTIVA filing
New York, January 20, 2026, 08:14 (EST) — Premarket ImmunityBio (IBRX.O) shares rose about 27% to $7 in premarket trading on Tuesday, with about 4.1 million shares changing hands, after the company said it had made progress with the U.S. Food and Drug Administration on a path to revive a label-expansion push for its bladder cancer treatment ANKTIVA. (Public) The…